David Nolan

10.1k total citations · 2 hit papers
149 papers, 7.3k citations indexed

About

David Nolan is a scholar working on Virology, Emergency Medicine and Infectious Diseases. According to data from OpenAlex, David Nolan has authored 149 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Virology, 43 papers in Emergency Medicine and 40 papers in Infectious Diseases. Recurrent topics in David Nolan's work include HIV-related health complications and treatments (43 papers), HIV Research and Treatment (43 papers) and HIV/AIDS drug development and treatment (33 papers). David Nolan is often cited by papers focused on HIV-related health complications and treatments (43 papers), HIV Research and Treatment (43 papers) and HIV/AIDS drug development and treatment (33 papers). David Nolan collaborates with scholars based in Australia, United States and United Kingdom. David Nolan's co-authors include S. Mallal, Ian James, A. Martin, E. McKinnon, Elizabeth J. Phillips, Corey Moore, E. Hammond, Silvana Gaudieri, Campbell S. Witt and Cyril Mamotte and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David Nolan

139 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HLA-B*5701 Screening for Hypersensitivity to Abacavir

2008 1.2k citations S. Mallal, Elizabeth J. Phillips et al. profile →
Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

2002 1.0k citations S. Mallal, David Nolan et al. profile →

Peers

Countries citing papers authored by David Nolan

Since Specialization

Citations

This map shows the geographic impact of David Nolan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Nolan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Nolan more than expected).

Fields of papers citing papers by David Nolan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Nolan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Nolan. The network helps show where David Nolan may publish in the future.

Co-authorship network of co-authors of David Nolan

This figure shows the co-authorship network connecting the top 25 collaborators of David Nolan. A scholar is included among the top collaborators of David Nolan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Nolan. David Nolan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	VEXAS: A review of current understandings and emerging treatment strategies 2025 ·Frontiers in Immunology ·(unknown), (unknown), Andrew McLean‐Tooke, (unknown), David Nolan	0
2	Inflammatory and vascular biomarkers as predictors of all‐cause death and cardiovascular outcomes in an Australian community‐based cohort 2025 ·Physiological Reports ·Silvia Lee, Alison Castley, Matthew Knuiman, David Nolan, Frank Sanfilippo, Girish Dwivedi	1
3	Integrating Deloading into Strength and Physique Sports Training Programmes: An International Delphi Consensus Approach 2023 ·Sports Medicine - Open ·(unknown), Ben William Strafford, (unknown), Patroklos Androulakis‐Korakakis, David Nolan	5
4	The Effect of Hormonal Contraceptive Use on Skeletal Muscle Hypertrophy, Power and Strength Adaptations to Resistance Exercise Training: A Systematic Review and Multilevel Meta-analysis 2023 ·Sports Medicine ·David Nolan, Kelly L. McNulty, (unknown), Brendan Egan	11
5	Long-Term Associations between Human Cytomegalovirus Antibody Levels with All-Cause Mortality and Cardiovascular Outcomes in an Australian Community-Based Cohort 2022 ·Viruses ·Silvia Lee, (unknown), Alison Castley, Mark Divitini, Matthew Knuiman, Patricia Price, David Nolan, Frank Sanfilippo, Girish Dwivedi	2
6	A Novel Targeted Amplicon Next-Generation Sequencing Gene Panel for the Diagnosis of Common Variable Immunodeficiency Has a High Diagnostic Yield 2022 ·Journal of Molecular Diagnostics ·(unknown), Dianne De Santis, (unknown), Erika Della Mina, Sam Salman, Grace Thompson, David Nolan, Richard Loh, Dominic Mallon, Andrew McLean‐Tooke, Mina John, Stuart G. Tangye, Michael O’Sullivan, Lloyd D’Orsogna	6
7	Are there differences in lifting technique between those with and without low back pain? A systematic review 2019 ·Scandinavian Journal of Pain ·David Nolan, Kieran O’Sullivan, (unknown), (unknown), Benjamin Smith	41
8	A national study of the molecular epidemiology of HIV-1 in Australia 2005–2012 2017 ·PLoS ONE ·Alison Castley, Shailendra Sawleshwarkar, Rick Varma, Belinda L. Herring, Kiran Thapa, Dominic E. Dwyer, Doris Chibo, Nam Nguyen, Karen Hawke, Rodney M. Ratcliff, Roger Garsia, Anthony D. Kelleher, David Nolan, (unknown)	21
9	Altered regulatory T‐cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosis 2017 ·Clinical & Translational Immunology ·Anderson P. Jones, Stephanie Trend, Scott N. Byrne, Marzena J. Fabis‐Pedrini, Sian Geldenhuys, David Nolan, David R. Booth, William M. Carroll, Robyn Lucas, Allan G. Kermode, Prue H. Hart	23
10	Longitudinal Trends in Western Australian HIV-1 Sequence Diversity and Viral Transmission Networks and Their Influence on Clinical Parameters: 2000–2014 2015 ·AIDS Research and Human Retroviruses ·Alison Castley, Silvana Gaudieri, Ian James, (unknown), (unknown), Mina John, David Nolan	5
11	Elevated Plasma Soluble CD14 and Skewed CD16+ Monocyte Distribution Persist despite Normalisation of Soluble CD163 and CXCL10 by Effective HIV Therapy: A Changing Paradigm for Routine HIV Laboratory Monitoring? 2014 ·PLoS ONE ·Alison Castley, Cassandra Berry, Martyn A. French, Sònia Fernández, R. Krueger, David Nolan	32
12	HIV-related stigma and physical symptoms have a persistent influence on health-related quality of life in Australians with HIV infection 2013 ·Health and Quality of Life Outcomes ·S. Herrmann, E. McKinnon, (unknown), Christophe Lalanne, S. Mallal, David Nolan, Olivier Chassany, Martin Duracinský	74
13	Constrained Pattern of Viral Evolution in Acute and Early HCV Infection Limits Viral Plasticity 2011 ·PLoS ONE ·Katja Pfafferott, Silvana Gaudieri, Axel Ulsenheimer, Ian James, Malte Heeg, David Nolan, Mina John, Andri Rauch, S. Mallal, Andrew Lucas, Paul Klenerman, Helmut M. Diepolder, Michaela Lucas	29
14	Human Leukocyte Antigen Class I-Restricted Activation of CD8+ T Cells Provides the Immunogenetic Basis of a Systemic Drug Hypersensitivity 2008 ·Immunity ·(unknown), Lyudmila Kostenko, (unknown), Anthony W. Purcell, Nicholas A. Williamson, Zhenjun Chen, Lars Kjer‐Nielsen, Nicole A. Mifsud, Brian D. Tait, Rhonda Holdsworth, (unknown), David Nolan, W.A. Macdonald, Julia K. Archbold, (unknown), Debbie Marriott, S. Mallal, Mandvi Bharadwaj, Jamie Rossjohn, James McCluskey	1
15	Immune responses to abacavir in antigen-presenting cells from hypersensitive patients 2007 ·AIDS ·A. Martin, C. Almeida, Paul Cameron, Anthony W. Purcell, David Nolan, Ian James, James McCluskey, Elizabeth J. Phillips, Alan Landay, S. Mallal	45
16	A Visfatin Promoter Polymorphism Is Associated with Low‐Grade Inflammation and Type 2 Diabetes 2006 ·Obesity ·Yuanyuan Zhang, Lucia Gottardo, Ryan Thompson, Christine Powers, David Nolan, (unknown), Maria Cristina Marescotti, Angelo Avogaro, Alessandro Doria	61
17	Predisposition to nevirapine hypersensitivity associated with HLA-DRB10101 and abrogated by low CD4 T-cell counts 2004 ·AIDS* ·A. Martin, David Nolan, Ian James, Paul Cameron, Jean Keller, Corey Moore, Elizabeth J. Phillips, Frank Christiansen, S. Mallal	236
18	Thymidine analogue-sparing highly active antiretroviral therapy (HAART). 2003 ·PubMed ·David Nolan, S. Mallal	10
19	Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? 2003 ·PubMed ·David Nolan, Silvana Gaudieri, S. Mallal	38
20	Longitudinal associations between antiretroviral treatments and quantification of tissue mitochondrial DNA from ambulatory subjects with HIV infection 2003 ·Murdoch Research Repository (Murdoch University) ·Catherine L. Cherry, David Nolan, (unknown), S. Mallal, E. McKinnon, Martyn A. French, E. Hammond, Michelle E. Gahan, J. McArthur, Steve Wesselingh	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact